Cancer-associated mucins show antigenic differences from normal mucins, and aberrant mucin O-glycosylation in cancer gives rise to tumor-associated antigens such as the Tn determinant (alpha-GalNAc-O-Ser/Thr) that has been explored as a potential target for immunotherapy (4, 5). This evidence concerns the gene MUC5AC and neoplasm.